Evidence map›Paper›PMID 40069783›Full record

ArticleJournal of translational medicine2025

CNV-mediated dysregulation of the ceRNA network mechanism revealed heterogeneity in diffuse and intestinal gastric cancers.

Rongji Xu, Danni He, Rui Sun, Jiaqi Zhou, Mengyu Xin, Qian Liu, Yifan Dai, Houxing Li, Yujie Zhang, Jiatong Li and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Rongji Xu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Danni He *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Rui Sun *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Jiaqi Zhou *The First Clinical School of Gansu University of Chinese Medicine, Lanzhou, 730030, China.
Mengyu XinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Qian LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yifan DaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Houxing LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yujie ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Jiatong LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
XinXin ShanCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yuting HeCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Borui XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Qiuyan GuoThe First Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Shangwei NingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. ningsw@ems.hrbmu.edu.cn.
Yue GaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. gaoyue_hrm@163.com.
Peng WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. wpgqy@hrbmu.edu.cn.ORCID 0000-0002-5716-9937

Funding

China Postdoctoral Science Foundation 2023T160172National Natural Science Foundation of China 32370718National Natural Science Foundation of China 82373408Natural Science Foundation of Heilongjiang Province YQ2024C040
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is a highly heterogeneous tumour with high morbidity. Approximately 95% of GC cases are gastric adenocarcinomas, which are further categorized into two predominant subtypes: diffuse gastric cancer (DGC) and intestinal gastric cancer (IGC). These subtypes exhibit distinct pathophysiological and molecular characteristics, reflecting their unique tumorigenic mechanisms.

methodIn this study, we employed a comprehensive approach to identify driver genes associated with DGC and IGC by focusing on copy number variation (CNV) genes within the competing endogenous RNA (ceRNA) network. The influence of driver CNV genes on the molecular, cellular, and clinical differences between DGC and IGC was subsequently analysed. Finally, therapeutic strategies for DGC and IGC were evaluated based on the status and functional pathways of the driver CNV genes.

resultsA total of 17 and 22 driver CNV genes were identified in DGC and IGC, respectively. These genes drive subtype differences through the ceRNA network, resulting in alterations in the tumour microenvironment (TME). Based on these differences, personalized treatment strategies for DGC or IGC could be developed. Immune checkpoint inhibitors may be an effective treatment option in IGC. Additionally, DGC patients with homozygous deletion of PPIF might benefit from adjuvant chemotherapy, whereas those with high-level amplification of MTAP could respond to targeted therapy.

conclusionDriver CNV genes were identified to reveal the underlying cause of heterogeneity in DGC and IGC. Furthermore, specific driver CNV genes were identified as potential therapeutic targets, facilitating personalized treatment.

Indexed as

DNA Copy Number VariationsGene Regulatory NetworksGenetic HeterogeneityIntestinal NeoplasmsStomach NeoplasmsGene Expression Regulation, NeoplasticHumansRNA, Competitive EndogenousTumor MicroenvironmentRNA, Competitive EndogenousCeRNACNVDiffuse gastric cancerDriver genesIntestinal gastric cancerTumour heterogeneity

Identifiers

PMID40069783
PMCPMC11895245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.